FrancophonIA/ELRC3.0 huggingface dataset:
English: HAE attacks are accompanied by an increased release of bradykinin, which is the key mediator in the development of the clinical symptoms.
Maltese: L-attakki ta' HAE huma akkumpanjati minn rilaxx akbar ta' bradykinin, li huwa lmedjatur prinċipali fl-iżvilupp tas-sintomi kliniċi.
English: Pharmacotherapeutic group: Other haematological agents, drugs used to treat hereditary angioedema;
Maltese: Mediċini wżati għat-trattament ta' anġjoedema ereditarja Kodiċi ATC:
English: A total of 66 patients with attacks of HAE affecting the larynx were treated in these controlled Phase III clinical trials.
Maltese: Total ta' 66 pazjent b'attakk ta' HAE li affettwa l-larinġi ġew ikkurati f'dawn il-provi kliniċi ta' Fażi
English: Patients experiencing a laryngeal attack should always seek medical advice and be observed in a medical institution also after having taken the injection at home.
Maltese: Pazjenti li jesperjenzaw attakk larinġeali għandhom dejjem ifittxu parir mediku u għandhom jiġu osservati f'istituzzjoni medika wkoll wara li jkunu ħadu injezzjoni mid-dar.
English: Each pre-filled syringe contains 30 milligrams of icatibant (as acetate).
Maltese: Kull siringa mimlija għal-lest fiha 30 milligramma (bħala aċetat).
English: How should Firazyr be administered?
Maltese: Kif għandu jingħata Firazyr?
English: Your doctor will tell you when it is safe for you to go home. After discussion with your doctor or nurse and after training in subcutaneous (under the skin) injection technique, you may be able to inject yourself with Firazyr or your caregiver may inject Firazyr for you when you have an HAE attack.
Maltese: Wara diskussjoni mat-tabib jew mal-infermier tiegħek u wara taħriġ fit-teknika ta' injezzjoni taħt il-ġilda, inti tkun tista' tinjetta lilek innifsek b'Firazyr jew min ikun qed jieħu ħsiebek ikun jista' jinjetta Firazyr għalik meta jkollok attakk tal-HAE.
English: Placebo p-value
Maltese: Valur-p
English: The injection solution contains less than 1 mmol (23 milligrams) of sodium, so it is essentially ‘sodium-free'.
Maltese: Is-soluzzjoni għal injezzjoni fiha anqas minn 1 mmol (23 milligramma) sodju, għalhekk hija prattikament ‘mingħajr sodju'.
English: Gastrointestinal disorders
Maltese: INFORMAZZJONI GĦALL-UTENT
English: Do not use this medicine after the expiry date stated on the label after ‘EXP'.
Maltese: Tużax din il-mediċina wara d-data ta' meta tistadi li tidher fuq it-tikketta wara ‘JIS'.
English: Caregiver/self-administration
Maltese: ANNESS I SOMMARJU TAL-KARATTERISTIĊI
English: Tranexamic acid
Maltese: TIKKETTA TAS-SIRINGA
English: For adults, subsequent doses that may be required for the same attack should be administered within a medical institution (see section 4.2).
Maltese: Għall-adulti, dożi sussegwenti li jistgħu jkunu meħtieġa għall-istess attakk għandhom jingħataw f'istituzzjoni medika (ara sezzjoni 4.2).
English: HAE manifests as intermittent attacks of subcutaneous and/or sub mucosal oedema involving the upper respiratory tract, the skin and the gastrointestinal tract.
Maltese: L-effetti sekondarji konnessi ma' Firazyr huma simili għas-sintomi tal-marda tiegħek.
English: The pharmacokinetics of icatibant has been characterized by studies using both intravenous and subcutaneous administration to healthy volunteers and patients.
Maltese: TWISSIJA SPEĊJALI LI L-PRODOTT MEDIĊINALI GĦANDU JINŻAMM
English: Change in Composite Investigator-Assessed Symptom Score at 2 hours
Maltese: Ħin għat-Titjib Inizjali Viżiv fis-Sintomi Vvalutat minn Investigatur (sigħat)
English: No clinically significant changes in reproductive hormones were observed during clinical studies.
Maltese: Matul l-istudji kliniċi ma ġie osservat l-ebda tibdil klinikament sinifikanti fl-ormoni riproduttivi.
English: Table 1: Dosage regimen for children and adolescents Body Weight
Maltese: Tabella 1: Reġimen tad-dożaġġ għat-tfal u għall-adolexxenti Piż tal-Ġisem
English: The primary efficacy endpoint was the time to onset of symptom relief using a visual analogue scale (VAS).
Maltese: III, l-endpoint primarju ta' l-effikaċja kien il-ħin sal-bidu tas-solljiev mis-sintomi bl-użu ta' visual analogue scale (VAS).
English: What Firazyr looks like and contents of the pack
Maltese: Id-dehra ta' Firazyr u l-kontenuti tal-pakkett
English: Patients were randomized to receive either icatibant 30 mg or placebo by subcutaneous injection.
Maltese: Il-pazjenti ġew randomizzati sabiex jirċievu jew icatibant 30 mg jew plaċebo b'injezzjoni taħt il-ġilda.
English: In the clinical trial, not more than 1 injection of Firazyr per HAE attack has been administered.
Maltese: Fil-prova klinika, ma ngħatatx aktar minn injezzjoni 1 ta' Firazyr għal kull attakk tal-HAE.
English: In both rats and dogs, repeated use of icatibant resulted in effects on reproductive organs.
Maltese: Kemm fil-firien kif ukoll fil-klieb, użu ripetut ta' icatibant irriżulta f'effetti fuq l-organi riproduttivi.
English: Firazyr may be administered by a caregiver only after training in subcutaneous injection technique by a healthcare professional.
Maltese: KONDIZZJONIJIET JEW RESTRIZZJONIJIET FIRRIGWARD TAL-UŻU SIGUR U EFFIKAĊI TAL-PRODOTT MEDIĊINALI
English: A subset of patients in this study experienced acute HAE attacks while receiving androgens, antifibrinolytic agents or Cl inhibitors.
Maltese: Subsett ta' pazjenti f'dan l-istudju esperjenza attakki ta' HAE akuti filwaqt li kien qiegħed jirċievi androġeni, sustanzi antifibrinolitiċi jew inibituri Cl.
English: Almost all subjects who were treated with subcutaneous icatibant in clinical trials developed reactions at the site of injection (characterised by skin irritation, swelling, pain, itchiness, erythema, burning sensation).
Maltese: Kważi l-persuni kollha li ġew ittrattati b'icatibant taħt il-ġilda fi provi kliniċi żviluppaw reazzjonijiet fis-sit ta' l-injezzjoni (ikkaratterizzati minn irritazzjoni tal-ġilda, nefħa, uġigħ, ħakk, eritema, sensazzjoni ta' ħruq).
English: In the pivotal juvenile toxicity study in which sexually immature rats were treated daily with 3 mg/kg/day for 7 weeks, atrophy of testes and epididymides were observed; the observed microscopic findings were partially reversible.
Maltese: Studju ta' ġimagħtejn ta' individwazzjoni tal-medda tad-doża taħt il-ġilda f'firien żgħar identifika 25 mg/kg/jum bħala l-aktar doża ttollerata.Fl-istudju pivotali tat-tossiċità fost iż-żgħar li fih, firien li kienu sesswalment immaturi ġew ikkurati kuljum bi 3 mg/kg/jum għal 7 ġimgħat, ġiet osservata atrofija tat-testikoli u tal-epididimidi; is-sejbiet mikroskopiċi osservati kienu parzjalment riversibbli.
English: For adults, up to 2 additional injections may be given within 24 hours.
Maltese: Għal pazjenti adulti, sa żewġ injezzjonijiet addizzjonali jistgħu jittieħdu f'24 siegħa.
English: --1 Attenuated infectious bursal disease virus, strain 1052, live, 101.48 to 102.63 PU* per dose * PU: Potency Units
Maltese: --1 Virus tal-marda bursali li jittieħed attentwat, razza 1052, ħaj, 101.48 sa 102.63 PU* għal kull doża * PU: Unitajiet tal-Potenza
English: EU Number Invented name
Maltese: Numru tal-UE Isem kummerċjali
English: EU/1/16/1100/001 Palonosetron Hospira
Maltese: EU/1/16/1100/001
English: 250 µg Solution for injection
Maltese: 250 µg Soluzzjoni għall-injezzjoni
English: Intravenous use vial (glass)
Maltese: Użu għal ġolvini
English: The educational material should include:
Maltese: • Jiġi enfasizzat:
English: o Patients weighing < 60 kg should have a reduced maintenance dose of 5mg o The evidence for a 5mg dose is based only on PK/PD analyses and no clinical data currently exist on the safety of this dose in the at risk sub groups.
Maltese: ○ Pazjenti li għandhom piż < 60 kg għandhom jieħdu doża mnaqqsa ta' manteniment ta' 5 mg ○ L-evidenza għad-doża ta'5 mg hija bbażata biss fuq l-analiżi PK/PD u f'dan ilmument ma jeżistix tagħrif kliniku dwar is-sigurtà ta' din id-doża f'dawk issottogruppi li huma taħt riskju.
English: • Emphasis that: o Severe haemorrhagic events are more frequent in patients ≥ 75 years of age (including fatal events) or those weighing < 60 kg o Treatment with prasugrel is generally not recommended for patients of ≥ 75 years of age.
Maltese: ○ Avvenimenti emorraġiċi serji huma iżjed frekwenti f'pazjenti ≥ 75 sena (inklużi avvenimenti fatali) jew dawk li għandhom piż < 60 kg ○ Normalment kura b'prasugrel mhux rakkomandat f'pazjenti ≥ 75 sena ○ Jekk, wara valutazzjoni individwali bir-reqqa mill-ispeċjalista li qed jippreskrivih il-kura f'dan il-grupp ta' età ta' pazjenti ≥ 75 sena tidher li tkun neċċessarja, mela mbagħad, wara d-doża ta' kkargar ta' 60 mg għandha tinkiteb riċetta ta' doża mnaqqsa ta' manteniment ta' 5 mg.
English: The MAH provides educational material to all physicians who may be involved in treating patients with prasugrel.
Maltese: L-MAH għandu jipprovdi materjal edukattiv lill-ispeċjalisti kollha li jistgħu jkunu involuti fil-kura ta' pazjenti b'prasugrel.
English: The format and means of dissemination, of this material should be discussed by the MAH with the appropriate learned societies.
Maltese: Il-mod u manjiera ta' kif għandu jitqassam dan il-materjal għandu jiġi diskuss mal-awtoritajiet involuti fil-kura tas-saħħa.
English: ATC vet code: QJ 01 XQ 01
Maltese: QJ 01 XQ 01
English: Felmingham, D. (May 2009) Report ‘Determination of the antimicrobial susceptibility of the VetPath II (2004-2006) collection of bacterial pathogens'.
Maltese: Report ‘Determination of the antimicrobial susceptibility of the VetPath II (2004-2006) collection of bacterial pathogens'.
English: 2370 Arendonk Belgium
Maltese: Hoge Mauw 900 2370 Arendonk Belgium
English: 9 CVMP note for guidance “Approach towards harmonisation of withdrawal periods” (EMEA/CVMP/036/95) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004428.pdf dose was in excess of the indicated dose (25 mg tiamulin hydrogen fumarate).
Maltese: 9 CVMP note for guidance “Approach towards harmonisation of withdrawal periods” (EMEA/CVMP/036/95) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004428.pdf
English: Tiamulin MICs are high against A. pleuropneumoniae.
Maltese: L-MICs ta' tiamulin huma għoljin kontra A. pleuropneumoniae.
English: 450 mg/g, correspon ds to 365 mg tiamulin/g
Maltese: 450 mg/g, correspond s to 365 mg tiamulin/g
English: 450 mg/g
Maltese: 450 mg
English: 55.6 g 111.2 g 1112 g 5000 g
Maltese: 2 g 1112 g 5000 g
English: and Gebhart, C.J. (2009) In vitro antimicrobial activity against 10 North American and European Lawsonia intracellularis isolates.
Maltese: In vitro antimicrobial activity against 10 North American and European Lawsonia intracellularis isolates.
English: McOrist and Gebhart (1995)4 found an intracellular minimum bactericidal concentration (iMBC) of <2 µg/ml in another strain.
Maltese: McOrist u Gebhart (1995)4 sabu konċentrazzjoni batteriċidali minima intraċellulari (iMBC, minimum bactericidal concentration) ta' <2 µg/ml f'razza oħra.
English: 6.1 List of excipients
Maltese: 6.1 Lista ta'ingredjenti Lactose
English: Currently further isolates have been tested from Korea (Yeh et al., 2011)6, Brazil and from Thailand (MAH proprietary data, 2016).
Maltese: Attwalment ġew ittestjati aktar iżolati mill-Korea (Yeh et al., 2011)6, mill-Brażil u mit-Tajlandja (data riżervata tal-MAH, 2016).
English: Interaction with other medicinal products and other forms of interaction:
Maltese: Interazzjonijiet ma prodotti mediċinali oħra u forom oħra ta' interazzjonijiet:
English: Lee, J.M.
Maltese: Kim, J.Y.
English: ALUMINIUM LAMINATE BAG
Maltese: BORŻA LAMINATA
English: eMIC50 was 4.0 µg/ml, eMIC90 8.0 µg/ml with an eMIC range of 1.0-32 µg/ml.
Maltese: L-eMIC50 kienet 4.0 µg/ml, eMIC90 8.0 µg/ml b'medda ta' eMIC ta' 1.0-32 µg/ml.
English: (equivalent to tiamulin 365 mg/g) Excipients:
Maltese: (ekwivalenti għal 365 mg ta'tiamulin)
English: Excretion is mainly via the bile (55-65%) and kidney (15-30%) as mainly microbiologically inactive metabolites and is quite rapid, 99% of the dose within 48 hours.
Maltese: It-tneħħija hi l-aktar permezz tal-bili (55-65%) u l-kliewi (15-30%), l-aktar bħala metaboliti mikrobijoloġikament inattivi, u hi pjuttost mgħaġġla, 99% tad-doża fi żmien 48 siegħa.
English: Annex III
Maltese: iii)
English: 6 Yeh, J.Y., J.H.
Maltese: Yeh, J.Y., J.H. Lee, H.R.
English: The epidemiological cut-off value was considered at 16 µg/ml which corresponds to the current Clinical and Laboratory Standards Institute (CLSI) standard (S ≤16 µg/ml, R ≥32 µg/ml).
Maltese: Il-valur tal-limitu epidemjoloġiku ġie kkunsidrat b'16 µg/ml li jikkorrispondi mal-istandard attwali tal-Istitut tal-Istandards Kliniċi u tal-Laboratorju (CLSI, Clinical and Laboratory Standards Institute) (S ≤16 µg/ml, R ≥32 µg/ml).
English: See section 4.8 for information regarding interaction between tiamulin and ionophores.
Maltese: Ara sezzjoni 4.8 għall-informazzjoni dwar l-interazzjoni bejn tiamulin u ionophores.
English: For five French isolates of M. meleagridis the MIC ranged from 0.03 - 0.06 µg/ml.
Maltese: Għal ħames iżolati Franċiżi ta' M. meleagridis l-MIC varjat minn 0.03 - 0.06 µg/ml.
English: Tiamulin has shown a high level of in vitro activity against porcine and avian Mycoplasma species as well as gram-positive aerobes (streptococci and staphylococci), anaerobes (clostridia), gram-negative anaerobes (Brachyspira hyodysenteriae, Brachyspira pilosicoli), and gram-negative aerobes (Actinobacillus pleuropneumoniae and Pasteurella multocida).
Maltese: Tiamulin wera livell għoli ta'attività in vitro kontra speċi Mycoplasma tal-qżieqeż u tat-tjur kif ukoll aerobjigram-pożittivi (streptokokki u stafilokokki), anaerobji (clostridia), anaerobjigram-negattivi (Brachyspira hyodysenteriae, Brachyspira pilosicoli), u aerobjigram-negattivi (Actinobacillus pleuropneumoniae u Pasteurella multocida).
English: At 0, 24, 36 and 48 hours after the last treatment, animals were necropsied and the entire liver was analysed for 8-α-hydroxymutilin based on a GC analytical method.
Maltese: F'0, 24, 36 u 48 siegħa wara laħħar kura, l-annimali ġew nekroskopijati u ġie analizzat il-fwied kollu għal 8-α-hydroxymutilin abbażi ta' metodu analitiku GC.
English: iMIC50 was 0.125 µg/ml, iMIC90 0.125 µg/ml with an iMIC range of 0.125-0.5 µg/ml.
Maltese: L-iMIC50 kienet 0.125 g/ml, iMIC90 0.125 µg/ml b'medda ta' iMIC ta' 0.125-0.5 µg/ml.
English: Lesion score reduction and reduction in microbiological re-isolation varied from 55% to 100% for prevention/metaphylaxis but were as low as 33% to 67% for treatment of M. gallisepticum.
Maltese: It-tnaqqis filpunteġġ tal-leżjonijiet u t-tnaqqis fl-iżolament mill-ġdid mikrobijoloġiku varjaw minn 55 % għal 100 % għall-prevenzjoni/metafilassi iżda kienu baxxi daqs 33 % sa 67 % għall-kura ta' M. gallisepticum.
English: • Enzootic Pneumonia caused by M hyopneumoniae, including infections complicated by Pasteurella multocida, or Pleuropneumonia caused by A. pleuropneumoniae: 20 mg tiamulin hydrogen fumarate (equivalent to 44.4 mg of product)/kg body weight administered daily for 5 consecutive days.
Maltese: Pulmonite Enzootika kkawżata minn M hyopneumoniae, inkluż infezzjonijiet ikkumplikati minn Pasteurella multocida, jew Plewropulmonite kkawżata minn A. pleuropneumoniae: 20 mg tiamulin hydrogen fumarate (ekwivalenti għal 44.4 mg ta' prodott)/kg piż tal-ġisem mogħti kuljum għal 5 ijiem konsekuttivi.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: Il-frekwenza ta'effetti mhux mixtieqa hija definita skont din il-konvenzjoni: - komuni ħafna (aktar minn wieħed f'10 annimali li juru effetti mhux mixtieqa matul il-perjodu ta'kura waħda) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal) - mhux komuni (aktar minn wieħed iżda inqas minn 10 annimali f'1,000 annimal) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal, inklużi rapporti iżolati).
English: Pigs, chickens
Maltese: Qżieqeż, tiġieġ
English: Belgium VMD nv Hoge Mauw 900
Maltese: VMD nv
English: It appears to be concentration-dependent with 500 mg tiamulin hydrogen fumarate (equivalent to 1.11 g of product) in 4 litres of water reducing intake by approximately 10% and 500 mg tiamulin hydrogen fumarate (equivalent to 1.11 g of product) in 2 litres of water by 15% in chickens.
Maltese: Jidher li hu dipendenti millkonċentrazzjoni b'500 mg ta'tiamulin hydrogen fumarate (ekwivalenti ghal 1.11 g ta' prodott) ma' 4 litri ilma li jnaqqas it-teħid b'madwar 10% u 500 mg ta' tiamulin hydrogen fumarate (ekwivalenti ghal 1.11 g ta' prodott) ma 2 litri ilma b'madwar 15% fit-tiġieġ.
English: The tiamulin MIC data determined for the available EU Lawsonia strains are all below the estimated ileal tiamulin contents of 0.63 μg/ml.
Maltese: Id-data MIC ta' tiamulin iddeterminata għar-razez Lawsonia tal-UE disponibbli hija kollha taħt il-kontenut ta' tiamulin ileali stmat ta' 0.63 μg/ml.
English: Wattanaphansak, S., Singer, R.S.
Maltese: Wattanaphansak, S., Singer, R.S. and Gebhart, C.J. (2009)
English: 8 Kucerova, Z., Hradecka, H., Nechvatalova, K. & Nedbalcova, K. (2011) Antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolates from clinical outbreaks of porcine respiratory diseases.
Maltese: Nedbalcova, K. (2011) Antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolates from clinical outbreaks of porcine respiratory diseases.
English: Pigs were treated at the intended dose and sacrificed 24 hours, 3, 4, 5 and 6 days after last administration.
Maltese: Il-ħnieżer ġew ikkurati bid-doża intiża u ġew issagrifikati 24 siegħa, 3, 4, 5 u 6 ijiem wara l-aħħar għoti.
English: Ninety three isolates of B. pilosicoli collected in Sweden (Pringle et al. 20061), 33 isolates collected in UK, Spain and Germany (MAH proprietary data 2008) as well as 324 isolates collected in Sweden between 2002 and 2010 (Pringle et al. 20122) were tested.
Maltese: Ġew ittestjati tlieta u disgħin iżolat ta' B. pilosicoli miġbura fl-Iżvezja (Pringle et al. 20061), 33 iżolat miġbura fir-Renju Unit, fi Spanja u fil-Ġermanja (data riżervata tal-MAH 2008) kif ukoll 324 iżolat miġbura fl-Iżvezja bejn l-2002 u l-2010 (Pringle et al. 20122).
English: Tiamulin hydrogen fumarate 450 mg
Maltese: Kull g fiha: Tiamulin hydrogen fumarate 450 mg
English: For the full list of excipients, see section 6.1.
Maltese: Għal-lista sħiħa t tal--ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
English: Wattanaphansak et al. (2009)5, tested 10 isolates of L. intracellularis (six from USA, four from Europe).
Maltese: (2009)5, ittestjaw 10 iżolati ta' L. intracellularis (sitta mill-Istati Uniti, erbgħa mill-Ewropa).
English: At 60 ppm tiamulin hydrogen fumarate equivalent to 8-9 mg tiamulin hydrogen fumarate/kg body weight administered for three to five days the infected pigs showed significant improvements in clinical endpoints, pathological signs and elimination of B. hyodysenteriae.
Maltese: B'60 ppm tiamulin hydrogen fumarate ekwivalenti għal 8-9 mg tiamulin hydrogen fumarate/kg piż tal-ġisem mogħti għal tlett sa ħamest ijiem, il-ħnieżer infettati wrew titjib kbir f'punti finali klinċi, sinjali patoloġiċi u eliminazzjoni ta' B. hyodysenteriae.
English: Denagard 45% has also been shown to be efficacious for the treatment of Enzootic Pneumonia caused by M. hyopneumoniae including infections complicated by Pasteurella multocida.
Maltese: Intwera wkoll li Denagard 45 % huwa effikaċi għall-kura ta' Pulmonite Enzootika kkawżata minn M. hyopneumoniae inkluż infezzjonijiet ikkumplikati minn Pasteurella multocida.
English: There is little evidence for serious adverse reactions, except when it is used with the incompatible coccidiostatic ionophores monensin, salinomycin, and narasin.
Maltese: Hemm ftit evidenza għal reazzjonijiet avversi serji, ħlief meta jintuża mal-ionofori kokkidjostatiċi inkompatibbli monensin, salinomycin, u narasin.
English: A withdrawal period of 4 days was calculated based on residue concentrations in liver tissues using the WT1.4 calculation program and setting values below limit of quantification (LOQ) at ½ LOQ according to the CVMP note for guidance “Approach towards harmonisation of withdrawal periods” (EMEA/CVMP/036/95)9.
Maltese: Ġie kkalkulat perjodu tal-irtirar ta' 4 ijiem abbażi ta' konċentrazzjonijiet tar-residwi fit-tessuti tal-fwied bl-użu tal-programm ta' kalkolu WT1.4 u li stabbilixxa valuri taħt il-limitu ta' kwantifikazzjoni (LOQ, limit of quantification) b'½ LOQ skont in-nota tas-CVMP għall-gwida “Approċċ lejn l-armonizzazzjoni tal-perjodi tal-irtirar” (EMEA/CVMP/036/95)9.
English: Doses administered ranged from 8.8-20 mg tiamulin hydrogen fumarate/kg body weight for 5 days.
Maltese: Id-dożi mogħtija varjaw minn 8.8-20 mg tiamulin hydrogen fumarate/kg piż tal-ġisem għal 5 ijiem.
English: • Infectious Sinusitis and Airsacculitis caused by M. gallisepticum, M. synoviae and M. meleagridis: 40 mg tiamulin hydrogen fumarate (equivalent to 88.9 mg of product)/kg body weight administered daily for the period of 3 to 5 consecutive days
Maltese: Sinusite Infettiva u Airsacculitis kkawżati minn M. gallisepticum, M. synoviae u M. meleagridis: 40 mg hydrogen fumarate /kg (ekwivalenti għal 88.9 mg ta' prodott)/kg piż tal-ġisem mogħti kuljum għal perjodu ta' 3 sa 5 ijiem konsekuttivi
English: Tiamulin hydrogen fumarate is well absorbed in chickens (70-95%) after oral administration and reaches peak concentrations in 2-4 hours (Tmax 2.85 hours).
Maltese: Tiamulin hydrogen fumarate jiġi assorbit tajjeb fit-tiġieġ (70-95%) wara l-għoti orali, u jilħaq konċentrazzjonijiet massimi wara 2-4 sigħat (Tmax ta'2.85 sigħat).
English: In the field trials tiamulin was administered at inclusion rates of 125 - 250 ppm and estimated doses from 13.3 - 32.5 mg tiamulin hydrogen fumarate/kg body weight for three days.
Maltese: Fil-provi fuq il-post tiamulin ingħata fir-rati ta' inklużjoni ta' 125 - 250 ppm u f'dożi stmati minn 13.3 - 32.5 mg tiamulin hydrogen fumarate/kg piż tal-ġisem għal tlitt ijiem.
English: Susceptibility testing of L. intracellularis is challenging since this is an obligate intracellular organism.
Maltese: L-ittestjar tas-suxxettibbiltà ta' L. intracellularis huwa ta' sfida peress li dan huwa organiżmu intraċellulari obbligat.
English: Data reported from further studies (Felmingham, 20097; Kuzerova et al., 20118) confirm these findings with MIC50 and MIC90 of 8 µg/ml and 16 µg/ml resp. and MIC ranges of 0.25-16 µg/ml and 0.5-64 µg/ml.
Maltese: Kuzerova et al., 20118) tikkonferma dawn is-sejbiet b'MIC50 u MIC90 ta' 8 µg/ml u 16 µg/ml resp. u meded ta' MIC ta' 0.25-16 µg/ml u 0.5-64 µg/ml.
English: In the field trials tiamulin was administered at inclusion rates of 125 - 250 ppm or daily doses from 12.7 to 59.7 mg tiamulin hydrogen fumarate/kg body weight for three days.
Maltese: Fil-provi fuq ilpost tiamulin ingħata fir-rati ta' inklużjoni ta' 125 - 250 ppm jew f'dożi ta' kuljum minn 12.7 sa 59.7 mg tiamulin hydrogen fumarate/kg piż tal-ġisem għal tlitt ijiem.
English: The in vitro susceptibility of M. gallisepticum and M. synoviae from chickens and turkeys was tested intwo studies with isolates from European Member States collected from 2005-2007, and 2010-2013, and in one study with global isolates collected before 1997.
Maltese: Is-suxxettibbiltà in vitro ta' M. gallisepticum u M. synovia minn tiġieġ u dundjani ġiet ittestjata f'żewġ studji b'iżolati minn Stati Membri Ewropej miġbura mill-2005-2007, u mill-2010-2013, u fi studju wieħed b'iżolati globali miġbura qabel l-1997.
English: antibacterial for systemic use / Pleuromutilins / tiamulin
Maltese: Grupp farmako-terapewtiku: antibatterjali għal użu sistematiku / Pleuromutilins / tiamulin Kodiċi ATC veterinarja:
English: Turkeys Meat and offal: 6 days
Maltese: Laħam u ġewwieni tal-annimal: 6 ijiem
English: 450 mg/g Granules
Maltese: 450 mg/g Granijiet